Resonance shared a post by Jennifer Hylton, Global Network Coordinator, Global Neuroblastoma Network on LinkedIn, adding:
“Two approaches to treating resistant neuroblastoma:
‘Should we use bevacizumab or Dinutuximab with irinotecan and temozolomide to treat resistant neuroblastoma?’ Experts Dr. Benjamin Lerman and Dr. Paola Angelini join us May 7, 2026 (0830EST) to discuss these approaches and their impact in various global settings.
Join us for a great discussion and educational session.
RSVP / Join us here.”
Quoting Jennifer Hylton’s post:
“Looking forward to this international discussion! Join Us!
RSVP here.”
Other Articles Featuring Resonance and Jennifer Hylton on OncoDaily.